secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010560
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023
--------------------------------------------------------------------------------

- No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).
- Cash $5.9M as of Dec 31, 2022; expects to need additional financing to continue operations.
- Completed business combination with Larkspur Health in Dec 2022; began trading on Nasdaq under ZVSA.
- Plans investigator-initiated trial for VAR 200 in FSGS and up to two other renal indications in Q4 2023.
- IC 100 preclinical program to complete in 2023; IND submission expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/0001493152-23-010560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer